despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6. .

the data also revealed 66% of trusts who replied had at least one cancer patient forced to wait over six months to start treatment, and 69% had a worse longest wait than in 2010. . .

“such figures underline how vital it is that the government supports the nhs to improve waiting times this year.” .